Item 2.02 Results of Operations and Financial Condition.

On November 7, 2008, SCOLR Pharma, Inc. announced its financial results for the third quarter of 2008. A copy of the press release containing the announcement is attached to this current report as Exhibit 99.1.

Item 8.01 Other Events.

On November 6, 2008, SCOLR Pharma, Inc. announced top-line results from its pivotal clinical trial evaluating efficacy of extended-release ibuprofen. A copy of the press release is attached to this current report as Exhibit 99.2.

The information contained herein, including the exhibits attached and incorporated herein by reference, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filings.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description
99.1 SCOLR Pharma, Inc. press release, dated November 7, 2008.

99.2 SCOLR Pharma, Inc. press release, dated November 6, 2008.

---